TrialBritish journal of haematology2019

Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma.

Jayadev M Umakanthan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.